Web-based Genetic Research on Parkinson's Disease

Ongoing, Web-Based Genome-Wide Association Studies for Targeted Disease Initiatives

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01351467

Enrollment

13576

Registered

2011-05-11

Start date

2009-04-30

Completion date

2021-06-23

Last updated

2022-11-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's Disease

Keywords

Parkinson's, genetic, online, GWAS, genome wide association

Brief summary

The purpose of this study is to examine how genes and environment affect risk for Parkinson's disease.

Detailed description

23andMe has created a web-based Parkinson's research initiative to understand the genetic associations found between Parkinson's patients' DNA and their disease. To learn more, visit: https://www.23andme.com/pd/. You can participate in this research initiative without leaving home. If you are eligible to participate, we will send you an in-home 23andMe DNA kit at no cost. We will ask you short online surveys (15-20) about your Parkinson's journey, symptoms, and response to treatment. Enrollment is on-going and open to individuals who have been diagnosed with Parkinson's disease and are residents of the U.S. Participants receive access to ancestry information and uninterpreted genetic data. Participants will also receive regular updates on our research efforts and findings.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* diagnosis of Parkinson's disease by a physician

Exclusion criteria

* diagnoses other than Parkinson's, including: * progressive supranuclear palsy (PSP) * multiple system atrophy (MSA) * Shy-Drager syndrome * spinal cerebella ataxia (SCA) * atypical parkinsonism * parkinsonism due to medications, drug-induced parkinsonism * vascular parkinsonism * frontotemporal dementia with parkinsonism

Design outcomes

Primary

Measure	Time frame	Description
Saliva DNA test and online surveys with questions about Parkinson's disease experience, symptoms and response to treatment	Intermittent surveys every 6 months for up to 24 months	We want to learn how genes and environment could play role in Parkinson's disease risk and progression

Countries

United States

Outcome results